MedTrace Logo

Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

NCT05780840 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-03-23

No results posted yet for this study

Summary

What is the visible light protective effect of dihydroxyacetone in individuals with erythropoietic protoporphyria? This will be tested in this randomized blinded placebo controlled study.

Conditions

Interventions

OTHER

Dihydroxyacetone

Application of 10% dihydroxyacetone (2 mg per square cm skin)

OTHER

Placebo

Application of lotion to the skin (2 mg per square cm skin)

Sponsors & Collaborators

  • Bispebjerg Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05780840 on ClinicalTrials.gov